BR112012028556A2 - Indóis - Google Patents
IndóisInfo
- Publication number
- BR112012028556A2 BR112012028556A2 BRBR112012028556-4A BR112012028556A BR112012028556A2 BR 112012028556 A2 BR112012028556 A2 BR 112012028556A2 BR 112012028556 A BR112012028556 A BR 112012028556A BR 112012028556 A2 BR112012028556 A2 BR 112012028556A2
- Authority
- BR
- Brazil
- Prior art keywords
- indos
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33230910P | 2010-05-07 | 2010-05-07 | |
PCT/US2011/035336 WO2011140324A1 (en) | 2010-05-07 | 2011-05-05 | Indoles |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012028556A2 true BR112012028556A2 (pt) | 2014-04-01 |
Family
ID=44904072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRBR112012028556-4A BR112012028556A2 (pt) | 2010-05-07 | 2011-05-05 | Indóis |
Country Status (33)
Country | Link |
---|---|
US (5) | US8536179B2 (pt) |
EP (2) | EP3246027A1 (pt) |
JP (1) | JP5864545B2 (pt) |
KR (1) | KR20130062290A (pt) |
CN (1) | CN102970869B (pt) |
AU (1) | AU2011248068B2 (pt) |
BR (1) | BR112012028556A2 (pt) |
CA (1) | CA2798622C (pt) |
CL (1) | CL2012003110A1 (pt) |
CR (1) | CR20120565A (pt) |
CY (1) | CY1119006T1 (pt) |
DK (1) | DK2566327T3 (pt) |
DO (1) | DOP2012000282A (pt) |
EA (1) | EA023788B1 (pt) |
ES (1) | ES2627085T3 (pt) |
HR (1) | HRP20170736T1 (pt) |
HU (1) | HUE034787T2 (pt) |
IL (1) | IL222878A (pt) |
LT (1) | LT2566327T (pt) |
MA (1) | MA34284B1 (pt) |
ME (1) | ME02757B (pt) |
MX (1) | MX2012012966A (pt) |
MY (1) | MY184101A (pt) |
NZ (1) | NZ603454A (pt) |
PE (1) | PE20130647A1 (pt) |
PL (1) | PL2566327T3 (pt) |
PT (1) | PT2566327T (pt) |
RS (1) | RS55874B1 (pt) |
SG (1) | SG185431A1 (pt) |
SI (1) | SI2566327T1 (pt) |
UA (1) | UA110112C2 (pt) |
WO (1) | WO2011140324A1 (pt) |
ZA (1) | ZA201208447B (pt) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
RU2618475C2 (ru) | 2010-09-10 | 2017-05-03 | Эпизайм, Инк. | Ингибиторы ezh2 человека и способы их применения |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
EP2646020B1 (en) * | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
ES2951688T3 (es) | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
AU2013203641B2 (en) * | 2011-04-13 | 2014-08-21 | Epizyme, Inc. | Aryl-or heteroaryl-substituted benzene compounds |
CA2850570A1 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
BR112014010803A2 (pt) | 2011-11-04 | 2017-04-25 | Glaxosmithkline Intellectual Property (No 2) Ltd | método de tratamento |
WO2013075084A1 (en) * | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
DK2794565T3 (da) | 2011-12-21 | 2017-11-13 | Novira Therapeutics Inc | Antivirale midler mod hepatitis b |
JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. | メチル基変更酵素の調節物質、組成物及びその使用 |
KR102453519B1 (ko) | 2012-03-12 | 2022-10-11 | 에피자임, 인코포레이티드 | 인간 ezh2의 억제제 및 이의 사용 방법 |
AU2013237226A1 (en) | 2012-03-19 | 2014-10-09 | Emory University | Quinazoline compounds and their use in therapy |
ES2617379T3 (es) * | 2012-04-13 | 2017-06-16 | Epizyme, Inc. | Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana |
WO2013173441A2 (en) * | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
JP2015522259A (ja) | 2012-06-14 | 2015-08-06 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | 化学実体とそれらの標的分子の間の相互作用を評価するゲノム全域法 |
CR20210079A (es) | 2012-08-28 | 2021-06-10 | Janssen Sciences Ireland Uc | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
CA2884848C (en) * | 2012-09-28 | 2017-08-22 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
RS59541B1 (sr) | 2012-10-15 | 2019-12-31 | Epizyme Inc | Metodi lečenja kancera |
EP2906538A4 (en) | 2012-10-15 | 2016-05-11 | Epizyme Inc | SUBSTITUTED BENZOL COMPOUNDS |
JP2016503009A (ja) | 2012-12-13 | 2016-02-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Zesteホモログ2エンハンサー阻害剤 |
WO2014100080A1 (en) * | 2012-12-19 | 2014-06-26 | Glaxosmithkline Llc | Combination |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
PE20160044A1 (es) * | 2013-02-11 | 2016-02-11 | Constellation Pharmaceuticals Inc | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos |
SI2961732T1 (sl) | 2013-02-28 | 2017-07-31 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
KR20150127216A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 암의 치료 및 암 약물 내성의 예방 방법 |
US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
WO2014153208A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
JP6581076B2 (ja) | 2013-03-14 | 2019-09-25 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤およびその使用 |
US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
EP2970131B1 (en) | 2013-03-14 | 2017-11-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2014153235A2 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970134B1 (en) | 2013-03-14 | 2018-02-28 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US9346761B2 (en) | 2013-03-14 | 2016-05-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970136A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2014155301A1 (en) * | 2013-03-26 | 2014-10-02 | Piramal Enterprises Limited | Substituted bicyclic compounds as inhibitors of ezh2 |
EP2981536B1 (en) | 2013-04-03 | 2017-06-14 | Janssen Sciences Ireland UC | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
KR20160003115A (ko) | 2013-04-30 | 2016-01-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 제스트 인핸서 상동체 2 억제제 |
PT2997019T (pt) | 2013-05-17 | 2018-11-21 | Janssen Sciences Ireland Uc | Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b |
JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
EP3004096A1 (en) * | 2013-06-06 | 2016-04-13 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
WO2015004618A1 (en) * | 2013-07-10 | 2015-01-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
ES2960953T3 (es) | 2013-10-16 | 2024-03-07 | Epizyme Inc | Forma de sal de clorhidrato para la inhibición de EZH2 |
SG11201602748XA (en) | 2013-10-23 | 2016-05-30 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2015077194A1 (en) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
EP3102225B1 (en) | 2014-02-05 | 2020-03-25 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
AP2016009257A0 (en) | 2014-02-06 | 2016-06-30 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20160340674A1 (en) * | 2014-02-10 | 2016-11-24 | University Of Rochester | Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases |
EP3111222A1 (en) | 2014-02-26 | 2017-01-04 | Glaxosmithkline Intellectual Property (No. 2) Limited | Methods of treating cancer patients responding to ezh2 inhibitor gsk126 |
US20170105997A1 (en) * | 2014-03-21 | 2017-04-20 | Northwestern University | Methods of treating cancer |
CN105037360B (zh) * | 2014-04-28 | 2016-08-17 | 四川大学 | 吡啶酮衍生物及其制备方法和用途 |
CN105017221B (zh) * | 2014-04-30 | 2019-05-28 | 中国医学科学院药物研究所 | 苯并咪唑衍生物及其制法和药物组合物与用途 |
EA031892B1 (ru) | 2014-06-17 | 2019-03-29 | Пфайзер Инк. | Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2 |
US20170217941A1 (en) * | 2014-06-25 | 2017-08-03 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
AU2015340614B2 (en) * | 2014-10-28 | 2018-07-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
EP3214935A4 (en) | 2014-11-06 | 2018-08-29 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
WO2016102493A1 (en) * | 2014-12-22 | 2016-06-30 | Bayer Pharma Aktiengesellschaft | Imidazopyridine ezh2 inhibitors |
WO2016101956A2 (en) | 2014-12-23 | 2016-06-30 | University Of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
EP3237418B1 (en) * | 2014-12-23 | 2019-01-30 | Novartis AG | Triazolopyrimidine compounds and uses thereof |
US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10961532B2 (en) | 2015-04-07 | 2021-03-30 | The General Hospital Corporation | Methods for reactivating genes on the inactive X chromosome |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
WO2017059059A1 (en) | 2015-09-29 | 2017-04-06 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
CA3000983A1 (en) | 2015-10-06 | 2017-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Method of treating medulloblastoma with an ezh2 inhibitor |
WO2017079738A1 (en) | 2015-11-05 | 2017-05-11 | Epizyme, Inc. | Flow cytometry for monitoring histone h3 methylation status |
RS59763B1 (sr) * | 2015-11-19 | 2020-02-28 | Jiangsu hengrui medicine co ltd | Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini |
CA3011186A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
AU2017217688B2 (en) | 2016-02-10 | 2023-01-19 | Wake Forest University Health Sciences | Model system of liver fibrosis and method of making and using the same |
EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
MX2018012557A (es) | 2016-04-15 | 2019-07-04 | Janssen Sciences Ireland Uc | Combinaciones y métodos que comprenden un inhibidor del ensamblaje de la cápside. |
EP3445365A4 (en) | 2016-04-22 | 2019-10-16 | Dana-Farber Cancer Institute, Inc. | EZH2 INHIBITORS AND USES THEREOF |
CN105777718B (zh) * | 2016-04-27 | 2019-03-19 | 上海应用技术学院 | 潜在ezh2小分子抑制剂及其合成方法 |
WO2017192290A1 (en) | 2016-05-04 | 2017-11-09 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs |
MA45406A (fr) | 2016-06-17 | 2019-04-24 | Epizyme Inc | Inhibiteurs d'ezh2 pour traiter le cancer |
WO2017221092A1 (en) * | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
CN107573327B (zh) * | 2016-07-05 | 2020-03-31 | 四川大学 | 吲唑-甲酰胺-吡啶酮衍生物及其制备方法和用途 |
CN107573336B (zh) * | 2016-07-05 | 2021-01-19 | 四川大学 | 苯并杂环-甲酰胺-吡啶酮衍生物及其制备方法和用途 |
EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
WO2018086590A1 (zh) * | 2016-11-11 | 2018-05-17 | 上海海雁医药科技有限公司 | 砜基取代的苯并杂环衍生物、其制法与医药上的用途 |
CN108699002B (zh) * | 2016-11-11 | 2021-11-09 | 上海海雁医药科技有限公司 | 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途 |
WO2018102687A2 (en) | 2016-12-02 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
AU2018210099A1 (en) | 2017-01-19 | 2019-08-15 | Daiichi Sankyo Company, Limited | Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
US20230201212A1 (en) | 2017-06-13 | 2023-06-29 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
MX2020004731A (es) | 2017-11-14 | 2020-10-28 | Pfizer | Terapias de combinacion de inhibidor ezh2. |
PL3746446T3 (pl) | 2018-01-31 | 2022-08-29 | Mirati Therapeutics, Inc. | Inhibitory PRC2 |
CN110229151B (zh) * | 2018-03-06 | 2021-09-10 | 上海海和药物研究开发股份有限公司 | 吲嗪类化合物、其制备方法及用途 |
WO2019175657A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
US20210308141A1 (en) * | 2018-07-27 | 2021-10-07 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Polysubstituted benzene compound and preparation method and use thereof |
MX2021010145A (es) | 2019-02-22 | 2021-09-14 | Janssen Sciences Ireland Unlimited Co | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. |
CN109761960B (zh) * | 2019-02-25 | 2021-08-31 | 江苏豪森药业集团有限公司 | 抗耐药抗肿瘤egfr抑制剂的制备方法 |
WO2020225230A1 (en) | 2019-05-06 | 2020-11-12 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
KR20220066892A (ko) | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법 |
CN113307765A (zh) * | 2021-05-24 | 2021-08-27 | 上海泰坦科技股份有限公司 | 吡啶甲胺类化合物及其制备方法 |
WO2023025856A1 (en) | 2021-08-25 | 2023-03-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ezh2 inhibitors for the treatment of aortic valve stenosis |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2584713B1 (fr) | 1985-07-11 | 1988-09-09 | Roussel Uclaf | Nouveaux derives de l'indole carboxamide, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant |
DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
JP4869068B2 (ja) * | 2003-06-19 | 2012-02-01 | スミスクライン ビーチャム コーポレーション | 化合物 |
PE20060748A1 (es) | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
CA2679175C (en) * | 2007-02-26 | 2015-01-13 | Merck Frosst Canada Ltd. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
US20090012031A1 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
AR070398A1 (es) | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
JP2012503651A (ja) | 2008-09-26 | 2012-02-09 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 3−デアザネプラノシン誘導体 |
WO2012005805A1 (en) * | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
US8846935B2 (en) * | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
ES2951688T3 (es) * | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
-
2011
- 2011-05-05 UA UAA201213880A patent/UA110112C2/uk unknown
- 2011-05-05 MA MA35415A patent/MA34284B1/fr unknown
- 2011-05-05 DK DK11778334.0T patent/DK2566327T3/en active
- 2011-05-05 KR KR1020127031955A patent/KR20130062290A/ko active IP Right Grant
- 2011-05-05 HU HUE11778334A patent/HUE034787T2/en unknown
- 2011-05-05 SI SI201131210A patent/SI2566327T1/sl unknown
- 2011-05-05 EA EA201291194A patent/EA023788B1/ru not_active IP Right Cessation
- 2011-05-05 ES ES11778334.0T patent/ES2627085T3/es active Active
- 2011-05-05 RS RS20170410A patent/RS55874B1/sr unknown
- 2011-05-05 NZ NZ603454A patent/NZ603454A/en not_active IP Right Cessation
- 2011-05-05 PT PT117783340T patent/PT2566327T/pt unknown
- 2011-05-05 WO PCT/US2011/035336 patent/WO2011140324A1/en active Application Filing
- 2011-05-05 PE PE2012002134A patent/PE20130647A1/es not_active Application Discontinuation
- 2011-05-05 MX MX2012012966A patent/MX2012012966A/es active IP Right Grant
- 2011-05-05 EP EP17162229.3A patent/EP3246027A1/en not_active Withdrawn
- 2011-05-05 PL PL11778334T patent/PL2566327T3/pl unknown
- 2011-05-05 EP EP11778334.0A patent/EP2566327B1/en active Active
- 2011-05-05 BR BRBR112012028556-4A patent/BR112012028556A2/pt not_active Application Discontinuation
- 2011-05-05 CN CN201180033600.2A patent/CN102970869B/zh not_active Expired - Fee Related
- 2011-05-05 MY MYPI2012700879A patent/MY184101A/en unknown
- 2011-05-05 AU AU2011248068A patent/AU2011248068B2/en not_active Ceased
- 2011-05-05 CA CA2798622A patent/CA2798622C/en not_active Expired - Fee Related
- 2011-05-05 ME MEP-2017-126A patent/ME02757B/me unknown
- 2011-05-05 JP JP2013509259A patent/JP5864545B2/ja not_active Expired - Fee Related
- 2011-05-05 SG SG2012081501A patent/SG185431A1/en unknown
- 2011-05-05 LT LTEP11778334.0T patent/LT2566327T/lt unknown
- 2011-05-05 US US13/696,362 patent/US8536179B2/en not_active Expired - Fee Related
-
2012
- 2012-11-02 DO DO2012000282A patent/DOP2012000282A/es unknown
- 2012-11-05 IL IL222878A patent/IL222878A/en active IP Right Grant
- 2012-11-06 CL CL2012003110A patent/CL2012003110A1/es unknown
- 2012-11-06 CR CR20120565A patent/CR20120565A/es unknown
- 2012-11-09 ZA ZA2012/08447A patent/ZA201208447B/en unknown
-
2013
- 2013-08-07 US US13/961,044 patent/US8975291B2/en not_active Expired - Fee Related
-
2015
- 2015-01-23 US US14/603,660 patent/US9114141B2/en not_active Expired - Fee Related
- 2015-07-09 US US14/794,911 patent/US9402836B2/en not_active Expired - Fee Related
-
2016
- 2016-06-20 US US15/186,633 patent/US9649307B2/en not_active Expired - Fee Related
-
2017
- 2017-05-05 CY CY20171100488T patent/CY1119006T1/el unknown
- 2017-05-16 HR HRP20170736TT patent/HRP20170736T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012028556A2 (pt) | Indóis | |
DE102011100241A8 (de) | Nitridhalbleiterbauteil | |
CR20130111A (es) | Triazina-oxidiazoles | |
DE10170954T8 (de) | Mikrowellendruckgarer | |
DE112011104226A5 (de) | Käfigmutter | |
DE102011117046A8 (de) | Doppelkupplungswindungsgetriebe | |
DE112011101226A5 (de) | Linearwegmesssystem | |
DE112011102080A5 (de) | Kupplungszentralausrücker | |
DK2442899T3 (da) | Rotorskive | |
DK2539163T3 (da) | Dækventil | |
DE102011002623A8 (de) | Ventilsteuerzeitversteller | |
DE112011102711A5 (de) | Hydrostataktor | |
DK2448659T3 (da) | Rotorskive | |
DK2447426T3 (da) | Vaske-WC | |
DE102010019119B8 (de) | Cuttermesser | |
DE112010005518A5 (de) | Dichtungsmanchette | |
DE102010038420A8 (de) | Reinigungungsvorrichtung | |
DK2596072T3 (da) | Bor-forbindelses-suspension | |
DK2521486T3 (da) | Palpometer | |
CO6801789A2 (es) | N-hetarilmetil pirazolilcarboxamidas | |
DE112011101796A5 (de) | Redoxakkumulatoranlage | |
DE102010035554B8 (de) | Fußtüröffner | |
DK2404809T3 (da) | Trækbjælke | |
DE112011104385A5 (de) | Tierleiteinrichtung | |
DE102010037356B8 (de) | Verdichterradkühlung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B65X | Notification of requirement for priority examination of patent application | ||
B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |